Stryker Gains FDA 510(k) for OptaBlate Bone Tumor Ablation

Stryker Optablate Bone Tumor Ablation System

Stryker was granted FDA 510(k) clearance to market the OptaBlate bone tumor ablation system. The addition of the OptaBlate technology to Stryker's Interventional Spine portfolio expands on its procedures for vertebral augmentation and radiofrequency ablation, and completes its portfolio of treatment options for metastatic vertebral body...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us